Skip to main content

Advertisement

Table 2 Kaplan-Meier mean and median ages at first use of NV in patients with DMD

From: Influence of β2 adrenergic receptor genotype on risk of nocturnal ventilation in patients with Duchenne muscular dystrophy

  Mean Age Median Age
Estimate (yrs) SE 95% CI Estimate (yrs) SE 95% CI
Arg16 25.91* 1.31 23.35–28.49 28.30* 4.14 20.19–36.41
Gly16 21.80 0.59 20.86–23.42 22.17 0.40 21.38–22.96
Overall 22.71 0.62 21.49–23.93 22.48 0.39 21.72–23.24
  1. SE standard error, CI confidence interval, Arg16: patients who were homozygous or heterozygous for the β2-adrenergic receptor (ADRB2) resulting in at least one arginine substitution at amino acid 16 (n = 26); Gly16: patients who were homozygous for ADRB2 resulting in a glycine substitution at amino acid 16 (n = 147). *Significant difference in mean or median age at first use of NV between genotype groups, P < 0.05